Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.39 |
| ▸ | ACHE | P22303 | 7/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12513083 | 0.82 | ALOX15 (0.38) | EPHX1HDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL10037314 | 0.82 | TDP1 (0.47) | EPHX1TSHRALDH1A1 | |
| SCHEMBL10243672 | 0.81 | EPHX1 (0.54) | EPHX1ACHETSHR | |
| SCHEMBL15145438 | 0.80 | EPHX1 (0.44) | EPHX1HDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL11982011 | 0.79 | EPHX1 (0.40) | EPHX1HDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL14754715 | 0.79 | EPHX1 (0.44) | EPHX1HDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL18236761 | 0.78 | EPHX1 (0.61) | EPHX1ACHETSHR | |
| SCHEMBL12852149 | 0.76 | CYP2C19 (0.47) | TSHR | |
| SCHEMBL12300324 | 0.74 | MEN1 (0.45) | EPHX1TSHR | |
| SCHEMBL464486 | 0.74 | SAT1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2012-01-05 | — | — | US | disclosed |
| US-20100247669-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247669-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | EPHX1 2184/4885HDAC1 2302/4885HDAC6 86/4885 |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | EPHX1 3709/4885HDAC1 720/4885HDAC6 126/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | EPHX1 880/4885HDAC1 2997/4885HDAC6 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.